Le Lézard
Classified in: Health
Subjects: CCA, TRI, FVT

Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801. 


Oramed Pharmaceuticals Logo


Call information:

Date: November 18, 2019
Time: 8:30 ET
Conference ID: 9469607
Webcast: ORMP Investor Event Webcast
Domestic dial-in:
International dial-in: +44 (0) 207-192-8000

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (PODtm) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 and Type 1 diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901, which has potential to be the first orally-ingestible GLP-1 analog.

For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes, the safety and efficacy of ORMD-0801or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission. 

Company Contact

Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001
US: +1-844-9-ORAMED
Email: estee@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

These press releases may also interest you

at 15:33
PreventionGenetics is excited to announce the availability of their new whole genome sequencing (WGS) test, PGnome®. Prices start at only $2,490 for testing of a single patient. WGS is the ultimate germline DNA test. It is superior to exome and other...

at 15:32
Sustained acoustic medicine (sam®) from ZetrOZ heals a wide range of injuries and relieves the pain caused by them - and the wearable device is covered by personal injury and workers' compensation insurance. The safe and effective treatment...

at 15:21
Boehringer Ingelheim today announced new analyses of the Phase III INBUILD® trial that studied Ofev® (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. These analyses were published...

at 15:00
A July 10 article on BBC News reports on the global rise of cosmetic procedures despite the ongoing COVID-19 pandemic. The article reports that as plastic surgeons have tightened health and safety measures in their clinics in response to the health...

at 14:59
Central Texas-based biotechnology startup Industrial Genetics today announces the launch of its proprietary genetic testing technology to identify the virus that causes COVID-19 (SARS-CoV-2), on surfaces and in wastewater. The test, available for use...

at 14:55
Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, has announced that enrollment is officially complete for their FDA approved stem cell clinical trial for  treatment of knee osteoarthritis. 38 patients are participating...

News published on 14 november 2019 at 07:28 and distributed by: